<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03403803</url>
  </required_header>
  <id_info>
    <org_study_id>160280</org_study_id>
    <nct_id>NCT03403803</nct_id>
  </id_info>
  <brief_title>Prognosis and Therapeutic Biomarkers for Glioblastoma Patients</brief_title>
  <official_title>Prognosis and Therapeutic Biomarkers for Glioblastoma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if the potential biomarkers identified could be
      used for facilitating the diagnosis and prognosis of patients with glioblastoma (GBM).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this proposed study is to determine the expression levels of a panel of
      markers including CD133, CD44, ABCC3, TNFRSF1A, AKT1, IDH2, and MGMT in GBM tissues and the
      CSF, blood, and saliva from patients with GBM receiving different types of treatment (Optune
      only or Optune with TMZ) and the non-brain tumor patients (controls). Our aims are: 1) To
      compare the differences of CD44 between the control group and the combined cancer groups at
      baseline; and 2) To compare the levels of CD44 and other markers among the 3 different groups
      such as control vs. GBM patients and Optune vs. Optune + TMZ after 8 weeks of treatment.
      Exploratory analysis of all other markers will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Were not able to meet enrollment goal due to inclusion/exclusion criteria
  </why_stopped>
  <start_date type="Actual">September 1, 2017</start_date>
  <completion_date type="Actual">March 25, 2019</completion_date>
  <primary_completion_date type="Actual">March 25, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Outcome - CD44 expression in cerebrospinal fluid (CSF), blood and saliva</measure>
    <time_frame>2 years</time_frame>
    <description>Currently, Glioblastoma is only diagnosed and monitored with brain scans. Expression levels of CD44 along with CD133, ABCC3, TNFRSF1A, AKT1, IDH2 and MGMT in samples of CSF, blood and saliva from patients receiving different types of treatment and comparing them with non-GBM patients (control group) will be tested.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">10</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Optune Only</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Optune and TMZ</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optune</intervention_name>
    <description>Optune is a wearable and portable, FDA-approved device that has been shown in clinical trials to safely deliver continuous therapy to the area of your brain where your GBM (Glioblastoma) tumor is located.
TMZ (Temozolomide) is an oral chemotherapy drug. It is an alkylating agent used as a treatment of some brain cancers; as a second-line treatment for astrocytoma and a first-line treatment for glioblastoma multiforme.</description>
    <arm_group_label>Optune Only</arm_group_label>
    <arm_group_label>Optune and TMZ</arm_group_label>
    <other_name>TMZ</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood, saliva and CSF (cerebrospinal fluid)
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosed with GBM or diagnosed with other neurological disorder that requires a lumbar
        puncture.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  22 years old

          -  Control Group (only patients evaluated for neurological disorders whose evaluation
             require a lumbar puncture)

          -  Non-Control Group - Diagnosed with GBM (Glioblastoma)

        Exclusion Criteria:

          -  Pregnancy

          -  Infectious Disease to include cold, flu, HIV, etc.

          -  Blood Disorder (example:low platelets, anemia, thrombosis)

          -  Vascular Malformations
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ekokobe Fonkem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Scott and White Medical Center, Temple, TX</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Baylor Scott and White Medical Center</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>November 9, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2018</study_first_posted>
  <last_update_submitted>March 25, 2019</last_update_submitted>
  <last_update_submitted_qc>March 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>Brain Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 7, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03403803/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Main Consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03403803/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form: Control Consent</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 9, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/03/NCT03403803/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

